Pivotal Therapeutics Exhibiting at European Society of Cardiology Congress 2012

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health, is pleased to announce that the company will be
exhibiting at the European Society of Cardiology (ESC) Congress 2012
in Munich, Germany August 25-29, 2012, Hall A2 Booth #B440. The ESC
Congress is the largest meeting of Cardiologists in Europe and a
forum for the latest research in cardiovascular disease, both
clinical and experimental. It is a renowned Medical Trade Show that
attracts delegates from all over the world.

The scientific data demonstrating the superiority of
VASCAZEN(TM)'s formulation recently presented at the 17th World
Congress on Heart Disease - Annual Scientific Sessions has been
expanded and these additional findings will be presented at the ESC
Congress. The presentation will take place on Monday August 27, 2012
at 16:30 in Tripoli Village 1. The study, entitled The highly
purified EPA:DHA 6:1 product evokes potent endothelium-dependent
relaxations of porcine coronary artery rings via the redox-sensitive
PI3-kinase/Akt-dependent phosphorylation of eNOS, was authored by F.
Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth and conducted at
the University of Strasbourg, Illkirch and France.

"Exhibiting at the ESC Congress is an important step in the
introduction of VASCAZEN[TM]to the European market" stated Dr. George
Jackowski, Chairman and Chief Scientific Officer of Pivotal
Therapeutics. "We are absolutely delighted that the Scientific Study
presented last month in Toronto, demonstrating the superiority of
VASCAZEN(TM)'s unique formulation, was chosen for presentation to
this international audience. We are eager to share these findings,
especially given the importance to patients with Coronary Heart
Disease."

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics' lead product
VASCAZEN[TM] is a prescription only Medical Food formulated to meet
the dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications.

VASCAZEN[TM] is a >90% pure, proprietary EPA:DHA fatty acid
formulation, protected by a series of both issued and pending US and
foreign patents and commercialized as a prescription only Medical
Food in the U.S. This unique formulation will provide the cornerstone
upon which a family of cutting edge combination products, with
efficacy across a broad spectrum of cardiac care, will be
commercialized.

OMAZEN[TM] is a >90% pure, proprietary EPA:DHA fatty acid
formulation commercialized for sale and distribution in Canada for
the maintenance of good health through elevating Omega-3 fatty acid
levels. The unique formulation and dosage will be available to
patients and consumers who realize the health benefits of Omega-3
supplementation with a quality product.

Disclosure Notice

The information contained in this document is as of August 23,
2012. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSNX listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. CNSX has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

For further information:
Company Contacts:
Rachelle MacSweeney
President and Chief Operating Officer
Phone: +1-905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us
Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us
Pivotal Therapeutics Inc.
http://www.pivotaltherapeutics.us

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de